Methylprednisolone Online



How and where to order Medrol, Depo-Medrol (Methylprednisolone) 4 mg, 8 mg, 16 mg, 32 mg tablets or capsules online on Noah's Wish website:

Shop:DFH PHARMACY
Stores:PHARMA DOCTOR
Prices:from $0.61 per pill
Discount:10% coupon: DFHDCC
Forms:4, 8, 16, 32 mg pills
Quantity:10-360 pills
Type:Methylprednisolone brand, Medrol generic, Depo-Medrol generic
Payment:Visa, MasterCard, AmEx, eCheck (ACH), Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Methylprednisolone (trade names include Medrol, Advantan, Depo-Medrate, Depo-Medrol, Depo-Medrone, Hexilon, Hysone, Ivepred, Lemod-Solu, Medixon, Medrol Dose Pak, Medrol-A, Medrone, Melsone, Meprelon, Mepresone, Cadista Methylprednisolone, Neodrol, Oro-Medrol, Predmet, Predni-M, Solomet, Solu-Medrol, Stenirol, Urbason, Zempred) is a synthetic glucocorticoid (GCS) medication from corticosteroid for topical and systemic use pharmacological groups. This medicine is used for the treatment of various medical conditions, such as skin diseases, allergic disorders, inflammatory conditions, endocrine (hormonal) disorders, autoimmune diseases, certain blood disorders, rheumatic disorders, breathing disorders, asthma, chronic obstructive pulmonary disease (COPD), bronchial inflammation, acute bronchitis, croup, shock, allergic rhinitis, arthritis, rheumatoid arthritis, osteoarthritis, gout, adrenogenital syndrome, ulcerative colitis, lupus, systemic lupus erythematosus, acne, pimples, dermatitis, psoriasis, plaque psoriasis, dermatologic lesion, certain cancers, tumor, multiple sclerosis, transverse myelitis, tuberculosis, vestibular neuronitis, neuralgia, Crohn's disease; to prevent the body from rejecting the embryos for a cycle of in vitro fertilization; for immunosuppression; in veterinary medicine; and for other diseases and medical disorders. It works by preventing the release of some substances in the body that cause inflammation.


Medrol (Methylprednisolone) tablets


Related medications:

  • Allopurinol (Zyloprim)
  • Betamethasone (Diprolene)
  • Budesonide, Formoterol (Symbicort)
  • Celecoxib (Celebrex)
  • Clobetasol (Temovate)
  • Colchicine (Colcrys)
  • Cortisone (Cortone)
  • Dexamethasone (Dexone)
  • Diclofenac (Voltaren)
  • Eplerenone (Inspra)
  • Etoricoxib (Arcoxia)
  • Fluocortolone (Ultralan)
  • Fluorometholone (FML)
  • Hydrocortisone (Solu-Cortef)
  • Indomethacin (Indocin)
  • Leflunomide (Arava)
  • Lidocaine (Xylocaine)
  • Loteprednol (Lotemax)
  • Mefenamic Acid (Ponstel)
  • Meloxicam (Mobic)
  • Mesalamine (Asacol)
  • Mesalazine (Pentasa)
  • Naproxen (Naprosyn)
  • Paramethasone (Depodillar)
  • Piroxicam (Feldene)
  • Prednisolone (Millipred)
  • Prednisone (Deltasone)
  • Prednylidene (Decortilen)
  • Rimexolone (Vexol)
  • Salbutamol (Albuterol)
  • Sulfasalazine (Azulfidine)
  • Triamcinolone (Aristocort)


    Pharmacological and medical categories:

  • Adrenals
  • Adrenocortical steroids
  • Anti acne medicines
  • Anti-inflammatory agents
  • Corticosteroid hormones
  • Eye corticosteroids
  • Medications for the treatment of dermatological diseases
  • Oestrogens and progesterones and related synthetic drugs
  • Topical corticosteroids
  • Veterinary, pet meds
  • Weak (group I) corticosteroids


    ATC codes:

  • D - Dermatologicals
  • D07 - Corticosteroids, dermatological preparations
  • D07A - Corticosteroids, plain
  • D07AA - Corticosteroids, weak (group I)
  • D07AA01 - Methylprednisolone

  • D07AC - Corticosteroids, potent (group III)
  • D07AC14 - Methylprednisolone Aceponate

  • D10 - Anti-acne preparations
  • D10A - Anti-acne preparations for topical use
  • D10AA - Corticosteroids, combinations for treatment of acne
  • D10AA02 - Methylprednisolone

  • H - Systemic hormonal preparations, excl. sex hormones and insulins
  • H02 - Corticosteroids for systemic use
  • H02A - Corticosteroids for systemic use, plain
  • H02AB - Glucocorticoids
  • H02AB04 - Methylprednisolone


    ICD-10 codes:

  • Tuberculosis - A15-A19
  • Acute Hepatitis A - B15
  • Other acute viral hepatitis - B17
  • Malignant neoplasm of bronchus and lung - C34
  • Follicular [nodular] non-Hodgkin's lymphoma - C82
  • Diffuse non-Hodgkin's lymphoma - C83
  • Multiple myeloma and malignant plasma cell neoplasms - C90
  • Lymphoid leukaemia - C91
  • Myeloid leukaemia - C92
  • Other disorders involving the immune mechanism, not elsewhere classified - D89
  • Adrenogenital disorders - E25
  • Multiple sclerosis - G35
  • Other demyelinating diseases of central nervous system - G37
  • Acute transverse myelitis in demyelinating disease of central nervous system - G37.3
  • Disorders of vestibular function - H81
  • Vestibular neuronitis - H81.2
  • Acute obstructive laryngitis [croup] and epiglottitis - J05
  • Acute obstructive laryngitis [croup] - J05.0
  • Acute bronchitis - J20
  • Vasomotor and allergic rhinitis - J30
  • Bronchitis, not specified as acute or chronic - J40
  • Other chronic obstructive pulmonary disease - J44
  • Asthma - J45
  • Crohn's disease [regional enteritis] - K50
  • Ulcerative colitis - K51
  • Atopic dermatitis - L20
  • Seborrhoeic dermatitis - L21
  • Allergic contact dermatitis - L23
  • Irritant contact dermatitis - L24
  • Lichen simplex chronicus and prurigo - L28
  • Other dermatitis - L30
  • Psoriasis - L40
  • Psoriasis vulgaris - L40.0
  • Other acute skin changes due to ultraviolet radiation - L56
  • Acne - L70
  • Acne, unspecified - L70.9
  • Other disorders of skin and subcutaneous tissue, not elsewhere classified - L98
  • Rheumatoid arthritis with rheumatoid factor - M05
  • Gout - M10
  • Other arthritis - M13
  • Osteoarthritis - M15-M19
  • Systemic lupus erythematosus (SLE) - M32
  • Dermatopolymyositis - M33
  • Other systemic involvement of connective tissue - M35
  • Ankylosing spondylitis - M45
  • Other and unspecified soft tissue disorders, not elsewhere classified - M79
  • Neuralgia and neuritis, unspecified - M79.2
  • Acute nephritic syndrome - N00
  • Chronic nephritic syndrome - N03
  • Nausea and vomiting - R11
  • Shock, not elsewhere classified - R57
  • Adverse effects, not elsewhere classified - T78
  • Encounter for procreative management - Z31
  • Encounter for assisted reproductive fertility procedure cycle - Z31.83


    Indications and usage:

    Medrol (Methylprednisolone) tablets are indicated in the following conditions:

  • Endocrine disorders
  • Rheumatic disorders
  • Collagen diseases
  • Dermatologic diseases
  • Allergic states
  • Ophthalmic diseases
  • Respiratory diseases
  • Hematologic disorders
  • Neoplastic diseases
  • Edematous states
  • Gastrointestinal diseases
  • Nervous system
  • Miscellaneous


    Dosage and administration:

    The initial dosage of Medrol tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Medrol should be discontinued and the patient transferred to other appropriate therapy.


    Dosage forms and strengths:

    Medrol (Methylprednisolone) tablets: 2 mg, 4 mg, 8 mg, 16 mg, 32 mg.


    Overdosage:

    Treatment of acute overdosage by methylprednisolone is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.


    Contraindications:

    Systemic fungal infections and known hypersensitivity to components.


    Warnings:

    In patients on corticosteroid therapy subjected to unusual stress, increased Medrol (Methylprednisolone) tablets dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

    Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.

    These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used.

    Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

    Usage in pregnancy

    Since adequate human reproduction studies have not been done with corticosteroids, the use of methylprednisolone in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

    Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

    Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.

    The use of Medrol tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

    If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

    Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.


    Precautions:

    Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

    There is an enhanced effect of corticosteroids, including Methylprednisolone (Medrol) on patients with hypothyroidism and in those with cirrhosis.

    Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

    The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

    Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

    Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

    Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

    Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

    Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

    Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.

    Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.


    Side effects, adverse reactions:

    Most common adverse reactions with Medrol (Methylprednisolone) tablets are:

  • Fluid and electrolyte disturbances
  • Muscle weakness
  • Pancreatitis
  • Pancreatitis
  • Abdominal distention
  • Impaired wound healing
  • Facial erythema
  • Convulsions
  • Vertigo
  • Headache
  • Suppression of growth in children
  • Menstrual irregularities
  • Posterior subcapsular cataracts
  • Increased intraocular pressure
  • Negative nitrogen balance due to protein catabolism


    Drug interactions:

    The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.

    Methylprednisolone (Medrol) may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.

    The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.


    Information for patients:

    Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.


    Pregnancy categories:

  • A - Australia
  • C - United States (Risk cannot be ruled out)


    Salts and other forms:

  • Methylprednisolone Base
  • Methylprednisolone Aceponate
  • Methylprednisolone Acetate
  • Methylprednisolone Cipionate
  • Methylprednisolone Hemisuccinate
  • Methylprednisolone Hydrogen Succinate
  • Methylprednisolone Sodium Hemisuccinate
  • Methylprednisolone Sodium Succinate
  • Methylprednisolone Suleptanate


    Synonyms, international and chemical names:

  • 1-Dehydro-6alpha-methylhydrocortisone
  • 6-Alpha-Methylprednisolone
  • Aceponato de Metilprednisolona
  • Bioprednon
  • Delta(1)-6alpha-Methylhydrocortisone
  • Methyleneprednisolone
  • Methyleprednisolone
  • Methylprednisolon
  • Methylprednisolonacetaat
  • Methylprednisolonacetat
  • Methylprednisolone, 6-Alpha
  • Methylprednisolone Na Succinate
  • Methylprednisolonhydrogensuccinat
  • Methylprednisoloni Acetas
  • Methylprednisoloni Hydrogenosuccinas
  • Methylprednisolonnatriumsuccinaat
  • Methylprednisolonum
  • Metilprednisolon
  • Metilprednisolona
  • Metilprednisolone
  • Metilprednizolon
  • Metyloprednizolon
  • Metylprednisolon
  • Metylprednisolone
  • Metyyliprednisoloni
  • Prednisolone, 6Alpha-Methyl-
  • Prednisolone, Methyl-
  • Prednol-L


    Brands, generics, trade names:

  • Advantan - Bayer, BioCSL, CSL, Firma Chun Cheong, Intendis, Invida, Jenapharm, Menarini, Schering, Schering-Plough, The Glory Medicina, Transfarma Medica Indah, Zuellig Pharma
  • Advantan Fatty Ointment - Bayer
  • Advantan Fettsalbe - Bayer
  • Advantan Milch - Bayer
  • Advantan Milk - Bayer
  • Depo-Medrate - Pfizer, Zoetis
  • Depo-Medrol - Pfizer, DKSH Distribution, Dr. Fisher Farma, Institute of Pharmaceutical Research and Technology, LF Asia Distribution, Max India, Perrigo, Primal Chemical, The Glory Medicina, Zoetis, Zuellig Pharma
  • Depo-Medrone - Pfizer, Institute of Pharmaceutical Research and Technology, MPT Pharma, Zoetis
  • Depo-Nisolone - Pfizer
  • Hexilon - Kalbe Farma
  • Hysone - Saviour Speciality
  • Ivepred - Sun Pharmaceutical Industries
  • Lemod-Solu - Hemofarm, Stada
  • Macpred - Macleods Pharmaceuticals, Macphar, Pushkar Pharmaceuticals
  • Medexa - Dexa Medica Pharm & Chem, DKSH
  • Medixon - Ferron, Dexa Medica Pharm & Chem, Ferron, Getz Brothers Philippines, Gracio Med Philippines, Shwe Yadanar Myay
  • Medrate - Pfizer
  • Medrol - Pfizer
  • Medrol Dose Pak - Pfizer
  • Medrol-A - Pfizer
  • Medrone - Pfizer, B & S Healthcare, Servipharm, Star Pharmaceuticals
  • Melpred - Cipla
  • Melsone - Psychotropics India
  • Meprelon - Sun-Farm
  • Mepresone - Dexa Medica Pharm & Chem, Cathay Drug
  • Mepresso-T - Intas Pharmaceuticals
  • Methylprednisolon - Acis Arzneimittelvertrieb, Jenapharm
  • Methylprednisolone - Cadista Pharmaceuticals, Mylan, Sandoz, Sopharma
  • Metilprednisolon - Teva
  • Metilprednisolona - Normon Laboratorios, Pisa Laboratorios
  • Metilprednizolon - Sopharma, Teva
  • Metipred - Chung Gei Pharma
  • Metypred - Galenpharma, Orion Pharma, Pharmacor Production, Sotex
  • Metysolon - Dermapharm
  • M-PredniHexal - Hexal
  • Neodrol - Neon Laboratories
  • Nucort-M - Mankind Pharmaceuticals
  • Oro-Medrol - Zoetis
  • Precort - Kocak Farma Ilac
  • Predace - Micro Labs
  • Predmet - Sun Pharmaceutical Industries, Milmet Pharma
  • Predni-M - Lichtenstein Pharmazeutica
  • Prednol - Mustafa Nevzat Ilac
  • Prednox - Pyridam Farma, One Pharma
  • Sanexon - Sanbe Farma
  • Solomet - Orion Pharma
  • Solu-Medrol - Pfizer, 2Care4 Medical, Eureco-Pharma, DKSH Distribution, Max India, Orifarm, Primal Chemical, The Glory Medicina, Zoetis, Zuellig Pharma
  • Stenirol - Guardian Pharmatama
  • Urbason - Sanofi-Aventis
  • Urbason Solubile - Sanofi-Aventis
  • Zempred - Sun Pharmaceutical Industries


    APIs used in medicine in combinations with methylprednisolone:

  • Aluminum Chlorohydrate
  • Aspirin
  • Bupivacaine
  • Indometacin
  • Lidocaine
  • Neomycin
  • Sulfur


    Here is a list of popular medications containing methylprednisolone as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Medrol
  • Tablets; Oral; Methylprednisolone 2 mg
  • Tablets; Oral; Methylprednisolone 4 mg
  • Tablets; Oral; Methylprednisolone 8 mg
  • Tablets; Oral; Methylprednisolone 16 mg
  • Tablets; Oral; Methylprednisolone 24 mg
  • Tablets; Oral; Methylprednisolone 32 mg
  • Pfizer
  • DKSH Distribution
  • Orifarm
  • Perrigo
  • Phytopharma
  • Primal Chemical
  • Techno Drugs
  • The Glory Medicina
  • Zoetis
  • Zuellig Pharma
  • Urbason
  • Tablets; Oral; Methylprednisolone 4 mg
  • Tablets; Oral; Methylprednisolone 8 mg
  • Tablets; Oral; Methylprednisolone 16 mg
  • Tablets; Oral; Methylprednisolone 40 mg
  • Sanofi-Aventis
  • Zempred
  • Tablets; Oral; Methylprednisolone 4 mg
  • Tablets; Oral; Methylprednisolone 8 mg
  • Tablets; Oral; Methylprednisolone 16 mg
  • Sun Pharmaceutical Industries



  • References:

  • Methylprednisolone main article on Wikipedia: https://en.wikipedia.org/wiki/Methylprednisolone
  • Methylprednisolone compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone
  • Methylprednisolone Acetate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone-acetate
  • Methylprednisolone Sodium Succinate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone-sodium-succinate
  • Methylprednisolone on DrugBank: https://www.drugbank.ca/drugs/DB00959
  • Methylprednisolone Acetate on DrugBank: https://www.drugbank.ca/salts/DBSALT001157
  • Methylprednisolone Sodium Succinate on DrugBank: https://www.drugbank.ca/salts/DBSALT001158
  • Methylprednisolone FAQ on MedlinePlus (revised 09/15/2017): https://medlineplus.gov/druginfo/meds/a682795.html
  • Methylprednisolone tablets drug label info on DailyMed (revised September 9, 2019): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Methylprednisolone containing drugs on Drugs-About.com: https://drugs-about.com/ing/methylprednisolone.html
  • Methylprednisolone for sale on Pharma Doctor: https://pharma-doctor.com/methylprednisolone.html
  • Methylprednisolone international drug names on Drugs.com: https://www.drugs.com/international/methylprednisolone.html
  • Medrol (Methylprednisolone) tablets official prescribing information from the U.S. FDA (revised July 2018): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Medrol (Methylprednisolone) tablets product information on Pfizer website (revised January 2019): https://www.pfizer.com/products/product-detail/medrol
  • Solu-Medrol (Methylprednisolone Sodium Succinate) for injection official prescribing information from the U.S. FDA (revised October 2011): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Solu-Medrol (Methylprednisolone Sodium Succinate) for injection product information on Pfizer website (revised 09/2020): https://www.pfizer.com/products/product-detail/solu_medrol
  • Medrol (Methylprednisolone) consumer information on RxList (revised 5/20/2020): https://www.rxlist.com/medrol-drug/patient-images-side-effects.htm
  • Medrone (Methylprednisolone) tablets 2 mg and 4 mg package information leaflet from Medicines.org.uk (revised 11/2018): https://www.medicines.org.uk/emc/files/pil.1085.pdf

    Revised: April 2021



    Home Page | About Us | How You Can Help | Volunteer | Privacy Policy | Contact Us

    Copyright © 2002 - 2021 Noah's Wish, Inc. All rights reserved.